Skip to content

DISCOVER: Dutch Iliac Stent trial: COVERed balloon-expandable versus uncovered balloon-expandable stents. A prospective, randomized, controlled, triple-blind, multi-center trial comparing PTFE-covered balloon-expandable stents versus uncovered balloon-expandable stents in patients with advanced occlusive disease of the common iliac artery in terms of morphologic, clinical, and hemodynamic outcome after a 2-year follow-up.

DISCOVER: Dutch Iliac Stent trial: COVERed balloon-expandable versus uncovered balloon-expandable stents. A prospective, randomized, controlled, triple-blind, multi-center trial comparing PTFE-covered balloon-expandable stents versus uncovered balloon-expandable stents in patients with advanced occlusive disease of the common iliac artery in terms of morphologic, clinical, and hemodynamic outcome after a 2-year follow-up. - Covered versus uncovered balloon-expandable iliac stents.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON41499
Enrollment
174
Registered
2012-04-02
Start date
2012-05-09
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arteriosclerosis of the leg Peripheral Arterial Occlusive Disease (PAOD)

Interventions

The control group will undergo endovascular dilatation or revascularization of the common iliac artery, followed by placement of one or more uncovered balloon-expandable stents. The study group will

Sponsors

Maasstadziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age over 18 - Symptomatic, atherosclerotic lesion of the common iliac artery, either a hemodynamically significant stenosis with a length of more than 3 cm, or an occlusion - Signed informed consent form

Exclusion criteria

Exclusion criteria: - Stenosis with a length of less than 3 cm - Presence of a metastatic malignancy, or other disease that limits life expectancy to less than two years. - Previous endovascular or surgical treatment of the common iliac artery on the affected side. - Inability or unwillingness to comply with the follow-up schedule. - Mental disability or language barrier that hinders the ability to understand and comply with the informed consent. - Pregnancy or breast-feeding. - Severe renal failure (e-GFR

Design outcomes

Primary

MeasureTime frame
Primary study parameters/endpoints: The primary endpoints are absence of binary restenosis rate, reocclusion rate and target-lesion revascularization rate. Primary study parameters are age, gender, relevant co-morbidity, and several patient, disease and procedure related parameters.

Secondary

MeasureTime frame
Secondary endpoints are clinical success, procedural success, hemodynamic success, major amputation rate, complication rate and mortality rate.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)